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Abstract
The complex growth patterns of malignant brain tumors can present challenges in
developing accurate models. In particular, the computational costs associated with
modeling a realistically sized tumor can be prohibitive. The use of high-performance
computing (HPC) and novel mathematical techniques can help to overcome this
barrier. This paper presents a parallel implementation of a model for the growth
of glioma, a form of brain cancer, and discusses how HPC is being used to take a
first step toward realistically sized tumor models. Also, consideration is given to the
visualization process involved with large-scale computing. Finally, simulation data
is presented with a focus on scaling.
Acknowledgments
The author would like to thank the following people for their support and guid-
ance:
• Dr. Kirk Jordan, IBM
• Dr. John Wagner, IBM
• Dr. Homer Walker, WPI
• Thomas Deisboeck, M.D., Massachusetts General Hospital
• Dr. Le Zhang, Massachusetts General Hospital
i
Contents
1 Introduction 1
2 Model Overview 2
2.1 Macroscopic environment . . . . . . . . . . . . . . . . . . . . . . . . . 2
2.2 Microscopic Environment . . . . . . . . . . . . . . . . . . . . . . . . . 3
2.2.1 EGFR Network . . . . . . . . . . . . . . . . . . . . . . . . . . 3
2.2.2 Cell Cycle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.3 Cell Phenotypes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
3 Parallel Implementation 8
3.1 Blue Gene/L System . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
3.2 Model Implementation . . . . . . . . . . . . . . . . . . . . . . . . . . 9
4 Simulation Results 11
4.1 Performance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
4.2 Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
5 Visualization 15
5.1 Deep Computing Visualization . . . . . . . . . . . . . . . . . . . . . . 15
6 Conclusions and Future Work 17
ii
List of Figures
2.1 Cell Signaling Pathways . . . . . . . . . . . . . . . . . . . . . . . . . 3
4.1 Visualization of Time Series Data . . . . . . . . . . . . . . . . . . . . 13
4.2 Cutplane Showing Multiple Isosurfaces. . . . . . . . . . . . . . . . . . 14
4.3 Imaging and Simulation: (a) Clinical MRI (b) Cell Density (c) Cell
Phenotype . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
5.1 Remote Visual Networking . . . . . . . . . . . . . . . . . . . . . . . . 16
5.2 Scalable Visual Networking . . . . . . . . . . . . . . . . . . . . . . . 16
iii
List of Tables
2.1 Variable Definitions and Initial Values . . . . . . . . . . . . . . . . . 7
4.1 Scaling Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
iv
Chapter 1
Introduction
Modeling a complex, biological system such as full-grown brain tumor is a difficult
task. There are a multitude of biological processes going on at different temporal and
spatial scales. In addition, problem sizes can grow enormously, requiring the use of
large, parallel systems. This project is an attempt to utilize high-performance com-
puting (HPC) to model a brain tumor of real-world size. A glioma model developed
by researchers at Massachusetts General Hospital has been adapted to run on IBM’s
Blue Gene/L supercomputer. It is a hybrid model that incorporates continuum de-
scription of the extracellular environment in which tumor cells reside and treats
tumor cells as individual agents, each with a unique genotype that is controlled by
a gene regulatory pathway model.
Manipulating the data generated by a machine of Blue Gene/L’s size can prove
troublesome, especially when trying to visualize the data. The results of the simu-
lations run on Blue Gene/L are presented here, and they make use of a unique vi-
sualization tool called Deep Computing Visualization (DCV), which was developed
by IBM to help in dealing with large data sets. In addition to the visualization,
scaling results are discussed. To advance to larger problem sizes, the model and its
parallel implementation must be able to run on 4,000+ processors without issue if
it is to provide novel insight into the growth of a brain tumor. Finally, the clinical
application of the model and Blue Gene/L’s role are discussed.
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Chapter 2
Model Overview
2.1 Macroscopic environment
We begin with a three-dimensional grid with each point being assigned a value for the
level of extracellular glucose (X14), oxygen tension (k44), and growth factor TGFα
(X1). These variables have initial conditions that are described by the following
normal distributions:
X1 = Tm e
−( 2d
σt
)2
(2.1)
X14 = Ga + (Gm −Ga) e
−( 2d
σg
)2
(2.2)
k1 = ka + (km − ka) e
−( 2d
σo
)2 . (2.3)
In (2.1), Tm is the maximum concentration of TGFα in the tumor, σt is a pa-
rameter that governs the dispersion of TGFα, and d is the distance from the initial
location. In (2.2) Gm is the maximum concentration of glucose in the blood and
Ga is the minimum blood glucose concentration. The parameter σg controls the
dispersion of glucose. Similarly, in (2.3) km is the maximum oxygen tension
1, ka is
the minimum oxygen tension, and σo is a parameter controlling the oxygen tension
dispersion [8]. For a detailed description of the variables presented here see Table
2.1 and for coefficient values see [1].
1Oxygen tension is the concentration of dissolved oxygen at which the partial pressure is in
equilibrium with the solvent
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2.2 Microscopic Environment
We now consider the model at a cellular level. Within each tumor cell there are
two systems: An epidermal growth factor receptor (EGFR) gene-protein interaction
network and cell cycle system. The EGFR network simulates the decision processes
involved with whether a cell proliferates or migrates and the cell cycle system deals
with the proliferation in more detail. Figure 2.1 shows a schematic of the EGFR
and cell cycle networks [1].
Figure 2.1: Cell Signaling Pathways
2.2.1 EGFR Network
In this model we will assume there are four layers that comprise a tumor cell and
its environment. Starting outside the cell is the extracellular material, then the
cell membrane, the cytoplasm, and finally the nucleus. Certain chemicals in the
extracellular material can bind to receptors in the cell membrane, resulting in a
reaction that impacts the internal environment of the cell. Specifically, TGFα(ex)
binds to the cell’s receptor EGFRs and two TGFα−EGFRex molecules are created
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(we will refer these as 2TGFα −EGFRs). In addition, a phosphate group is joined
to 2TGFα − EGFRs (a process called phosphorylation), resulting in the complex
2ppTGFα −EGFR. These reactions are modeled by the following system of ODEs
[1]:
dX1
dt
= k
−1X3 − k1X1X2 + k9X7 − k11X1 (2.4)
dX2
dt
= k
−1X3 − k1X1X2 + k8X6 − k−8X2 (2.5)
dX3
dt
= 2k1X1X2 − 2k−1X3 − k2X3 [1 + wgX13]
− k3X3 + k−2X4 +
VM2X11
KM2 +X11
X4 (2.6)
dX4
dt
= k2X3 [1 + wgX13]− k−2X1X4
− k4X4 −
VM2X11
KM2 +X11
X4. (2.7)
The variables X1, X2, X3, and X4 denote the molecules TGFα(ex), EGFRs,
2TGFα − EGFRs, and 2ppTGFα − EGFRs. The cell then internalizes 2TGFα −
EGFRs, resulting in cytoplasmic TGFα−EGFR (X5) which is then further broken
down into cytoplasmic TGFα (X6) and EGFR (X7). The cell may transcribe and
translate TGFα RNA (X8) and EGFR RNA (X9), and these RNA species, as well
as the protein involved (X12), may be degraded.
The phosphorylated TGFα − EGFR complex can increase the rate at which
inactive PLCγ (X10) is converted to active PLCγ (X11) which, in turn, inhibits
extracellular glucose (X14). Finally, the intake of extracellular glucose increases the
level of intracellular glucose (X13), which may also be reduced by TGFα − EGFR
phosphorylation or cell metabolism. Each of the processes is represented by the
following system of ODEs:
dX5
dt
= k3X3 + k4X4 + 2k−5X6X7 − 2k5X5 (2.8)
dX6
dt
= k5X5 − k−5X6X7 − k8X6 + k−8X2 + k12X8 − k6X6 (2.9)
dX7
dt
= k5X5 − k−5X6X7 − k9X7 + k15X9 + k7X7 (2.10)
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dX8
dt
= k13X12 − k14X8 (2.11)
dX9
dt
= k17X12 − k16X9 + k18X4 (2.12)
dX10
dt
= k21X11 − k20 (k29 −X11)X4 (2.13)
dX11
dt
= k20 (k29 −X11)X4 − k21X11 (2.14)
dX12
dt
= k16X9 − k14X8 − k13X12 − k17X12 (2.15)
dX13
dt
= k23X14 − k2X3X13 − k28X13. (2.16)
2.2.2 Cell Cycle
We now turn to the interior cell dynamics and examine the process involved with
determining if a cell divides. The central element here is a biological “on-off” switch
which is triggered by the mass of the cell (X17). This switch is influenced by cdh1-
APC complexes (X15) and cyclin-CDK (X16); a cell proliferates when X15 < k30 and
X16 > k31, where k30 and k31 denote the cdh1-APC and cyclin-CDK thresholds, re-
spectively. Also note that the effect of CDK can be inhibited by non-phosphorylated
retinoblastoma protein (X19), or RBNP [8]. The cell cycle is also affected by the
amount of oxygen and protein p27 (X18) present. If oxygen levels are high there will
be less protein p27 and, thus, a shorter cycle. Conversely, under hypoxic conditions
there will be more protein p27 and the cell cycle will be inhibited. Lastly, the mass
of the cell influences the amount of protein p27. The entire cell cycle is described
by the equations,
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dX15
dt
=
(1 + k32X19) (1−X15)
k34 + 1−X15
−
k33X15X16X17
k35 +X15
(2.17)
dX16
dt
= k39 − (k36 + k37X15 + k38X18)X16 (2.18)
dX17
dt
= k40X17
(
1−
X17
k41
)
(2.19)
dX18
dt
= k42
(
1−
X17
k41
)
−
(
k43
k44
k44 + k45
X18
)
(2.20)
dX19
dt
= k17X12 − k16X9 + k18X4. (2.21)
2.3 Cell Phenotypes
In this model we will assume that a tumor may enter one of four states: migration,
proliferation, quiescence, or apoptosis. We note that cells may proliferate or migrate,
but not simultaneously, and also each state is reversible except for apoptosis. A cell
will decide to migrate based on the level of PLCγ, which we will denote as the
threshold σPLC . If σPLC <
∣∣∣X ti+111 −X ti11
∣∣∣, where superscripts denote time steps,
the cell will enter a migratory state. Otherwise, the cell will proliferate or stay
quiescent. If a cell chooses to migrate it will evaluate its neighboring locations and
the determine the ideal one. This evaluation is described by the following:
Tj = ψLj + (1− ψ)ǫj (2.22)
In (2.22), Tj is the perceived attractiveness of location j, Lj is correct evaluation
of that location, ǫj ∼ N (u, σ
2) is an error term, and 0 ≤ ψ ≤ 1 is the search
precision [4]. The search precision governs how accurate the cell is in searching for
a location. If ψ = 1, then there is no error in how the cell perceives that location.
However, if ψ = 0 the tumor cell exhibits random-walk motion when searching for
a location.
If a cell chooses to proliferate then it will produce two identical daughter cells.
These cells begin in an “undecided” state and proceed to evaluate nutrient levels in
order to determine if they will become proliferative, quiescent, migratory, or apop-
totic. If a cell is unable to find an unoccupied location for migration or proliferation
it will become quiescent. Also, a cell may become quiescent if σPLC ≥
∣∣∣X ti+111 −X ti11
∣∣∣
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or if 0.8 ≤ X14 ≤ 1.6. Finally, if the glucose level is too low, i.e., X14 < 0.8, the cell
will become apoptotic.
Table 2.1: Variable Definitions and Initial Values
Variable Definition Initial Value
X1 TGFα extracellular protein 1
X2 EGFR cell surface receptor 25
X3 Dimeric TGFα − EGFR cell surface complex 0
X4 Phosphorylated active dimeric TGFα − EGFR
cell surface complexes
0
X5 Cytoplasmic inactive dimeric TGFα − EGFR
complex
0
X6 Cytoplasmic EGFR protein 0
X7 Cytoplasmic TGFα protein 1
X8 EGFR RNA 1
X9 TGFα RNA 0
X10 PLCγ, inactive, Ca-bound 1
X11 PLCγ, active, phosphorylated, Ca-bound 0
X12 Nucleotide pool 5
X13 Cytoplasmic glucose 1
X14 Extracellular glucose 0
X15 cdh1-APC complex 0.9
X16 cyclin-CDK 0.01
X17 Tumor cell mass 5
X18 Protein p27 0
X19 Non-phosphorylated retinoblastoma protein 1
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Chapter 3
Parallel Implementation
The computational aspects associated with modeling a brain tumor of a realistic
size can be prohibitive. Current models deal with tumor cell numbers on the order
of 105 − 107, whereas realistic brain tumors can be composed of 1010 − 1012 cells.
In addition to novel numerical methods, high-performance computers capable of
reaching the teraflops and petaflops scale are needed in order to tackle such problem
sizes.
3.1 Blue Gene/L System
One such system is the Blue Gene/L (BG/L) architecture that was developed jointly
by IBM and Lawrence Livermore National Laboratory. Blue Gene/L is currently the
world’s fastest supercomputer with a LINPACK benchmark of 280.8 Tflops and a
sustained 100 Tflops on a real-world application. It is a distributed memory machine
designed to contain a large number of processors in a small area while minimizing
power consumption.
A BG/L compute node contains 512MB of memory, dual 700MHz PowerPC
CPUs, each with a double-pipeline, double-precision floating point unit, and has
a peak performance of 5.6Gflops. The compute node is capable of operating in
two modes: co-processor or virtual node. In co-processor mode one processor is
dedicated to computation and the other is dedicated to communication, while in
virtual node mode each processor handles its own communication. A full BG/L
rack is composed 1024 compute nodes (or 2048 processors) with 512GB of memory
and 128 I/O nodes.
8
In addition, BG/L has five interconnect networks for communication, I/O, and
diagnostics. Of primary interest are the communication networks, which are a
three-dimensional torus network, a collective network, and a barrier network. The
three-dimensional torus network connects every node through a low-latency, high-
bandwidth network and allows for nodes to communicate with all other nodes. The
combination of BG/L’s toroidal network and its fast interconnect speeds make BG/L
well-suited for applications involving nearest-neighbor communications (such as the
above tumor growth model). The collective network allows for any node to broadcast
data to all other nodes (or any subset of nodes), as well as the global broadcasting
of data. Finally, the barrier network is used for global interrupts and barriers.
3.2 Model Implementation
To implement the tumor growth model on BG/L, an existing serial C++ program
was modified to incorporate the industry standard Message Passing Interface (MPI)
used for processor communication. Within the program we consider both a global
and a local (i.e., located on each processor) grid size. Based on the total number of
processors available and a specified local grid size, the program divides the domain
into smaller computational volumes. For example, suppose we perform a small run
on 64 processors (4 processors in the x-direction, 4 in the y-direction, and 4 in the
z-direction), each with a local size of 32 × 32 × 32 grid points. Then there will be
a total of 128× 128× 128 computational volumes and each processor is responsible
for 32,768 computational volumes.
The computations associated with each volume are divided into two categories:
those that deal with the macroscopic environment and those related to the intracel-
lular networks. The current model and its BG/L implementation have effectively no
computation associated with the macroscopic environment. Only the initial distribu-
tion for each molecular species (TGFα, glucose, and oxygen tension) is computed and
subsequent time steps require only that the level of each species be communicated
for a specific location. Regarding the intracellular networks, each computational
volume can contain one or more virtual tumor cells, and for each cell the system of
ODEs described in (2.4)-(2.21) must be solved. The solution is approximated us-
ing a classical second order Runge-Kutta scheme [7]. Once the local computations
are completed, each virtual tumor cell undergoes the phenotype decision process
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outlined in §2.3. A global sort identifies the phenotype of each virtual cell in each
computational volume. Cells that have proliferated or migrated to locations out-
side of their original processor are then sent to the appropriate processor, and the
algorithm repeats.
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Chapter 4
Simulation Results
Here we present the results of several simulations conducted on Blue Gene/L, as well
as several images obtained from the data set of a small run. The Blue Gene runs were
conducted on both an internal IBM machine and on Harvard’s School of Engineering
and Applied Sciences system (SEAS). The IBM Blue Gene is a custom configuration
containing only 128 compute nodes (256 processors or 1/8th of a standard Blue Gene
rack). Because the SEAS system is shared among researchers at Harvard, the IBM
system was used primarily for development and for small (8 and 64 processor) runs.
An IBM Z Pro Intellistation with Dual 2.8 GHz Intel Xeon processors and an nVidia
Quadro FX 2000 graphics card was used for rendering and also acted as the RVN
server. The Amira software package was used for the visualization and a Thinkpad
T60p functioned as the RVN client.
4.1 Performance
The simulations presented here were conducted on a 128x128x128 grid with a grid
spacing of 10 µm in each direction, and approximately 1,000 initial virtual tumor
cells. A standard forward-Euler method was used for the time-stepping algorithm. A
fixed time step of 10 seconds was used for 450,000 time steps, yielding a simulated
time period of approximately 52 days. A total of 19 variables were used, three
of which include extracellular molecular species and the rest correspond to the cell
signaling pathways. To demonstrate strong scaling the overall problem size was held
fixed while the local problem sized was decreased as more compute nodes were added.
The results are presented in Table 4.1. Note that in Table 4.1, one dual-processor
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compute node is used for comparison and the run time is taken from [1]. Also, the
simulations did not include input and output, which would have a significant impact
on the overall run time; these simulations were simply to focus on the computation
and to test scaling. For additional perspective, results from a 1024 × 1024 × 1024
grid are included for the the largest number of compute nodes.
Compute Nodes Run Time Speedup
1 25 hrs, 46 min 2 N/A
8 5 hrs, 34 min 1
64 42 min 7.95
512 5 min, 21 sec 62.4
512 43 hrs, 20 min 3 N/A
Table 4.1: Scaling Results
As we can see there is almost linear scaling as the number of compute nodes is
increased. The second 512 node in 4.1 run was conducted to examine the effects
of an increase in the global problem size. Simple calculations suggest that if we
were to use 4096 computes nodes (or 4 full Blue Gene/L racks) a simulation with
a 1024 × 1024 × 1024 grid size could be completed in 5 minutes, 25 seconds. The
fact that this model scales fairly well indicates that a very large simulation could be
completed in a reasonable amount of time. However, the issue of input and output
would need to be addressed.
4.2 Imaging
Several time steps from data generated by an 8 processor run are presented in
Figure 4.1. Black corresponds to necrotic cells, green for quiescent cells, red for
proliferative cells, and blue for migratory cells. As the tumor grows, we can see that
that hetereogeneity of the tumor’s interior has given way to a large necrotic center.
Figure 4.2 shows an alternate view with the interior of the tumor mass exposed and
the other isosurfaces visible.
The data generated here could possible be used in a clinical environment. Stan-
dard MRI (Fig. 4.3(a)) only provides images of cell density. Also, current MRI
2Using a 64× 64× 64 grid.
3Using a 1024× 1024× 1024 grid.
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(a) (b)
(c)
Figure 4.1: Visualization of Time Series Data
techniques don’t allow clinicians to see the beginning stages of a tumor. By cou-
pling MRIs with cell density data (Fig. 4.3(b)) and phenotypic data from simula-
tions (Fig. 4.3(c)) it would be possible to not only detect small tumors, but also
determine their makeup, thereby allowing for more specific treatments.
13
Figure 4.2: Cutplane Showing Multiple Isosurfaces.
(a) (b)
(c)
Figure 4.3: Imaging and Simulation: (a) Clinical MRI (b) Cell Density (c) Cell
Phenotype
14
Chapter 5
Visualization
Massively parallel systems like Blue Gene/L allow researchers to tackle complex,
large-scale problems. However, with larger problem sizes come larger data sets, as
well as the need to visualize them in a realistic time frame. When dealing with
large data sets users can be limited by software issues and insufficient hardware.
In an attempt to address these problems, IBM has developed the Deep Computing
Visualization (DCV) package. Deep Computing Visualization allows for existing,
OpenGL-based applications to be used in either an immersive, scalable environment
(Scalable Visual Networking or SVN) or for remote collaboration (Remote Visual
Networking or RVN).
5.1 Deep Computing Visualization
Remote Visual Networking allows users to remotely interact with a 3D application,
greatly increasing collaboration without requiring each user to have access to high-
end graphics workstations. DCV works as middleware between the 3D application
and the graphics processing unit (GPU), both of which are located on a server work-
station. When the application makes an OpenGL call to the GPU, RVN intercepts
the call and compresses the 3D data into 2D images which are then transferred, via
TCP/IP, to the remote users. This process places all of the GPU-intensive calcu-
lations on the server side and gives each remote user access to a high-end graphics
workstation without having to physically be at the workstation. It also reduces
the collaborators’ costs, as only one high-end graphics workstation is needed. In
addition, virtual network computing provides users with a graphical interface to
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the server workstation and also handles the transmission of mouse and keyboard
commands, 2D images, and any window or menu interfaces. Figure 5.1 shows the
process of RVN [5].
Figure 5.1: Remote Visual Networking
Scalable Visual Networking provides a method for displaying OpenGL applica-
tions on multiple, large-scale monitors. This is particularly useful when working
with a large group of people or when using an immersive environment. Much like
RVN, SVN intercepts the OpenGL calls but then, using MPI, distributes the 3D
geometry (note that it is uncompressed) across a high-speed network to a cluster
of workstations. Each workstation then renders a portion of the object, which is
then displayed, producing a scaled-up version of the original image in its entirety.
It should be noted that SVN and RVN may operate simultaneously. Figure 5.1
outlines SVN [5].
Figure 5.2: Scalable Visual Networking
16
Chapter 6
Conclusions and Future Work
The next step in improving the mathematical model is to incorporate diffusion of
oxygen, glucose, TGFα, and other molecular species. In addition, sources and sinks
such as blood vessels need to be included. At the microscopic scale, it may be
necessary to include other cellular pathways that model things like apoptosis or
cell stress. Of course, the inclusion of added pathways and diffusion will impact
what numerical method is utilized. An implicit time-stepping method, such as a
backward-differentiation formula (BDF) method [2], may be implemented in the
future; in the large-scale case of interest, this would entail using iterative linear
algebra methods such as the conjugate-gradient method [3] or GMRES [6] for the
linear subproblems.. Also, the addition of diffusion would introduce the possibility
of using a multiscale modeling approach. The diffusible variables could be approxi-
mated on one grid size while the cellular dynamics are approximated on another grid
size. Besides the grid sizing, variable time stepping could be used in the multiscale
modeling approach.
A more accurate tumor model, along with improved algorithms, could yield im-
pressive results. However, one must consider how theses will implemented and, more
importantly, optimized on a system such as Blue Gene/L. A robust implementation
would take full advantage of every processor available by using a load-balancing
scheme. The current tumor model performs an initial domain decomposition, but
as the tumor grows this decomposition remains static, which poses an issue. At later
time steps, the tumor has developed a large, necrotic center and only cells along the
surface are proliferating or migrating. In terms of computation, the necrotic center
corresponds to idle processors and the surface cells correspond to processors with
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very large workloads. A load-balanced implementation of the tumor model would
allow for the processors associated with the necrotic center to share the workload.
There are also areas in the visualization process that can be optimized. As of
now, the program writes a text file at each time step that contains the location
and phenotype of each virtual tumor cell, as well as data about glucose and TFGα.
For small runs this is an adequate solution, but even moderately sized runs can
produce text files of over 1GB in size. This poses a problem when 40-50 files are
generated and then must be moved and loaded into memory. A first step for the
current program would be to eliminate the variables from the text files that aren’t
visualized. This would help to reduce the overall size, but more can be done. Systems
like Blue Gene/L can produce enormous amounts of data faster than they can be
moved to a file system. By eliminating the file system, the memory requirements for
visualization would be drastically reduced. The visualization program would only
need to load in a single time step and then discard it after it has been rendered.
The model presented here and its parallel implementation demonstrate that the
modeling of realistically-sized brain tumors is in the near future. The scaling results
presented §4.1 show that the current model could be scaled to run on several racks
of Blue Gene/L with little modification. This is especially promising given that IBM
will soon announce the next generation Blue Gene/P, capable of petascale compu-
tation. Besides the computational results, we have seen how the Deep Computing
Visualization package can improve collaboration when working with HPC. However,
there are a number of improvements that can made to the mathematical model, the
parallel implementation, and the visualization process in order to reach the goal of
modeling modeling realistic brain tumors.
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